Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-Cell Lymphoma.

Trial Profile

Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Anaemia; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Jun 2012 Additional location (Portugal) added as reported by European Clinical Trials Database.
    • 05 Jun 2012 Final analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top